Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

Now Viewing

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?

Related Videos

Related Content

Advertisement

May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 15th 2025

Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits

Portia J. Zaire, PhD, RN A. Mark Fendrick, MD Jacob E. Kurlander, MD, MS Archana Radhakrishnan, MD, MHS

Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 14th 2025

Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use

Brooke McCormick

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

May 14th 2025

Lower Odds of Cataract Associated With Antioxidant Index

Julia Bonavitacola

A higher composite dietary antioxidant index was found to decrease the chances of American adults developing cataracts.

Related Content

Advertisement

May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 15th 2025

Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits

Portia J. Zaire, PhD, RN A. Mark Fendrick, MD Jacob E. Kurlander, MD, MS Archana Radhakrishnan, MD, MHS

Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 14th 2025

Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use

Brooke McCormick

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

May 14th 2025

Lower Odds of Cataract Associated With Antioxidant Index

Julia Bonavitacola

A higher composite dietary antioxidant index was found to decrease the chances of American adults developing cataracts.